Forecasted · Cooperative Agreement
Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)
Centers for Disease Control and Prevention - ERA, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)
- Issuing agency
- Centers for Disease Control and Prevention - ERA (Department of Health and Human Services)
- Opportunity number
- RFA-TS-27-018
- Funding type
- Cooperative Agreement
- Funding purpose
- Health
- Status
- Forecasted
- Application deadline
- Forecasted · estimated close December 1, 2026 (agency estimate)Agency note: Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date.
- Agency estimates
- Estimated posting: October 1, 2026. Estimated award date: August 29, 2027. Estimates can change.
- Published award range
- Up to $500,000
- Estimated total program funding
- $4,500,000
- Expected number of awards
- 3
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Others (see Additional Information on Eligibility)
- Unrestricted (open to any type of entity, subject to any clarification in Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov lists eligibility as Unrestricted. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.061
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/363115 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 363115 · Funding opportunity number RFA-TS-27-018
- Posted
- July 8, 2026 · Source last updated July 8, 2026
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 100% of key fields published by the source
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Eligibility details (from the agency)
Additional Eligibility Information to be included in the NOFO.
Description (from the official listing)
CDC/ATSDR is inviting research proposals to study risk factors for Amyotrophic Lateral Sclerosis (ALS). Studies on military service, contact sports, traumatic brain injury, neuroinflammation, and infections agents and exposures are encouraged. Funding will be for four funding options: Option A - Support research with strong existing evidence such as studies on known environmental or genetic risk factors, research that improves past studies with better data, or investigations linking risk factors to ALS diagnosis and treatment; Option B - Support new and exploratory research on ALS risk factors such as studies on risk factors with little existing evidence or research using innovative methods; Option C - Understand ALS risk in affected populations, such as studies involving military veterans or investigations of ALS risk factors impacting this population; Option D - Analyze biological samples from the Guamanian ALS cluster such as investigation of disease mechanisms and environmental factors, exposure routes, genetic studies and biomarkers and how this could lead to mitigation therapeutics, diagnostics or prevention.
Agency contact
Dr. Candis Hunter
ncipc_erpo@cdc.gov